GB201614387D0 - Improved vaccines - Google Patents

Improved vaccines

Info

Publication number
GB201614387D0
GB201614387D0 GBGB1614387.7A GB201614387A GB201614387D0 GB 201614387 D0 GB201614387 D0 GB 201614387D0 GB 201614387 A GB201614387 A GB 201614387A GB 201614387 D0 GB201614387 D0 GB 201614387D0
Authority
GB
United Kingdom
Prior art keywords
improved vaccines
vaccines
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614387.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1614387.7A priority Critical patent/GB201614387D0/en
Publication of GB201614387D0 publication Critical patent/GB201614387D0/en
Priority to PCT/EP2017/071232 priority patent/WO2018037045A1/en
Priority to BR112019003462A priority patent/BR112019003462A2/en
Priority to CA3034124A priority patent/CA3034124A1/en
Priority to MX2019002178A priority patent/MX2019002178A/en
Priority to CN201780065538.2A priority patent/CN109863169A/en
Priority to EP17768002.2A priority patent/EP3504230A1/en
Priority to US16/327,575 priority patent/US11498956B2/en
Priority to JP2019510818A priority patent/JP2019528072A/en
Priority to JP2022117354A priority patent/JP2022166002A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
GBGB1614387.7A 2016-08-23 2016-08-23 Improved vaccines Ceased GB201614387D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1614387.7A GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines
JP2019510818A JP2019528072A (en) 2016-08-23 2017-08-23 Fusion peptide in which antigen is linked to small fragment of invariant chain (CD74)
MX2019002178A MX2019002178A (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74).
BR112019003462A BR112019003462A2 (en) 2016-08-23 2017-08-23 fusion protein, polynucleotide, viral vector, pharmaceutical composition, use of a fusion protein, polynucleotide, viral vector or pharmaceutical composition, and method for treating or preventing viral hepatitis b infection or viral hepatitis c infection
CA3034124A CA3034124A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
PCT/EP2017/071232 WO2018037045A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
CN201780065538.2A CN109863169A (en) 2016-08-23 2017-08-23 The fusogenic peptide of antigen with the short-movie section for being connected to invariant chain (CD74)
EP17768002.2A EP3504230A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
US16/327,575 US11498956B2 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
JP2022117354A JP2022166002A (en) 2016-08-23 2022-07-22 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614387.7A GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines

Publications (1)

Publication Number Publication Date
GB201614387D0 true GB201614387D0 (en) 2016-10-05

Family

ID=57045505

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614387.7A Ceased GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines

Country Status (1)

Country Link
GB (1) GB201614387D0 (en)

Similar Documents

Publication Publication Date Title
GB201410971D0 (en) Vaccine
GB201622033D0 (en) No details
GB201714253D0 (en) No details
GB201518684D0 (en) Vaccine
PL3185899T3 (en) Improved hvt-vectored nd-ibd vaccine
IL249823A0 (en) Meningococcus vaccines
GB201702043D0 (en) No details
GB201709809D0 (en) No details
IL247159B (en) Pcsk9 vaccines
GB201522132D0 (en) Vaccine
GB201703185D0 (en) No details
IL277752A (en) Cancer vaccines
GB201616904D0 (en) Vaccine
HK1248560A1 (en) Dna-peptide combination vaccine
PL3469691T3 (en) Halbach-array configuration
GB201608821D0 (en) Vaccines
PL3188755T3 (en) Vaccine
GB201402083D0 (en) Retaining means
GB201709361D0 (en) No details
GB201605099D0 (en) HCV vaccines
GB201417214D0 (en) Vaccine
GB201614387D0 (en) Improved vaccines
GB201704892D0 (en) Improved vaccines
GB201712904D0 (en) Vaccine
GB201707785D0 (en) Vaccination

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)